Stockreport

Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment [Yahoo! Finance]

Compass Therapeutics, Inc.  (CMPX) 
PDF On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price targe [Read more]